219763-83-4

Basic information

• Product Name: 4-CHLORO-6-CYANOQUINOLINE
• Synonyms: 4-CHLORO-6-CYANOQUINOLINE;4-chloroquinoline-6-carbonitrile;4-Chloro-6-quinolinecarbonitrile;6-Quinolinecarbonitrile, 4-chloro-
• CAS NO: 219763-83-4
• Molecular Formula: C₁₀H₅ClN₂
• Molecular Weight: 188.61
• Mol File: 219763-83-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 340℃
• Flash Point: 160℃
• Appearance: /
• Density: 1.36
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: 4-CHLORO-6-CYANOQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-6-CYANOQUINOLINE(219763-83-4)
• EPA Substance Registry System: 4-CHLORO-6-CYANOQUINOLINE(219763-83-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 219763-83-4(Hazardous Substances Data)

Usage

General Description

4-Chloro-6-cyanoquinoline is a chemical compound with the molecular formula C10H5ClN2. It is a yellow solid with a molecular weight of 188.62 g/mol. 4-CHLORO-6-CYANOQUINOLINE is a derivative of quinoline and contains a chlorine and a cyano group. It is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 4-Chloro-6-cyanoquinoline has also been studied for its potential anti-inflammatory and antimicrobial properties. However, it is important to handle this chemical with care as it can be harmful if ingested, inhaled or come into contact with skin.

Upstream product

• 873-74-5 4-Aminobenzonitrile 
• 557-21-1 zinc(II) cyanide 
• 40107-07-1 4-chloro-6-iodo-quinoline 
• 642477-81-4 4-Hydroxy-6-quinolinecarbonitrile 
• 219763-81-2 4-[(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-ylidenemethyl)-amino]-benzonitrile 

Downstream Products

• 219763-87-8 4-bromoquinoline-6-carboxylic acid 
• 219763-85-6 4-bromoquinoline-6-carboxylic acid methyl ester 

Relevant articles and documents

A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics

Senexins are potent and selective quinazoline inhibitors of CDK8/19 Mediator kinases. To improve their potency and metabolic stability, quinoline-based derivatives were designed through a structure-guided strategy based on the simulated drug–target dockin

IRAK INHIBITORS AND USES THEREOF

The present invention provides quinazoline and quinoline compounds, compositions thereof, and methods of using the same. Also disclosed is the activity of such compounds as inhibitors of IRAK enzymes.

Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities

A simple two-step synthesis method was used to make 51 B-ring-substituted 4-hydroxyquinolines allowing analysis of the effect of ring substitutions on inhibition of growth of chloroquine sensitive and resistant strains of Plasmodium falciparum, the dominant cause of malaria morbidity. Substituted quinoline rings other than the 7-chloroquinoline ring found in chloroquine were found to have significant activity against the drug-resistant strain of P. falciparum W2.